Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The report covers the month of May 2025, specifically detailing a share repurchase executed on May 29, 2025. The filing is made pursuant to Rule 13a-16 under the Securities Exchange Act of 1934.
Key Financial Metrics and Transaction Details
The filing details a specific share buyback transaction rather than providing comprehensive financial statements (revenue, profit, or cash flow). Key metrics for the reported transaction include:
- Shares Purchased: 535,953 ordinary shares.
- Price Range: Lowest price paid was 1,434.50 GBp; highest price paid was 1,458.50 GBp.
- Average Price: Volume-weighted average price paid was 1,448.69 GBp.
- Trading Venue: London Stock Exchange (XLON).
- Broker: Citigroup Global Markets Limited.
Since the commencement of the current buyback programme on February 24, 2025, GSK has purchased an aggregate of 47,553,577 ordinary shares.
Material Changes and Capital Structure
Following the May 29, 2025 purchase, the company's capital structure reflects the following updates:
- Treasury Shares: GSK now holds 216,623,880 ordinary shares in treasury.
- Shares in Issue: There are 4,098,638,167 ordinary shares in issue (excluding treasury shares).
- Voting Rights: The total number of voting rights is 4,098,638,167.
- Treasury Voting Percentage: The percentage of voting rights attributable to treasury shares is 5.29%.
The filing does not provide comparative financial data (e.g., revenue or profit changes) versus prior periods as it is a transaction-specific report.
Guidance, Outlook, and Risks
The filing confirms that the purchase was part of an existing buyback programme executed under a non-discretionary agreement entered into on February 24, 2025. The purchased shares are held as Treasury shares.
Risk Factors: The document includes a cautionary statement regarding forward-looking statements. It notes that actual results may differ materially from projections due to risks and uncertainties, referencing the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and Q1 Results for 2025.
Investor Verification Checklist
- Verify the total number of treasury shares held (216,623,880) against the company's latest capitalization table.
- Confirm the remaining capacity under the buyback programme announced on February 24, 2025.
- Review the "Risk Factors" in the 2024 Form 20-F and Q1 2025 results for context on forward-looking statements.
- Check the denominator for voting rights calculations (4,098,638,167) for compliance with FCA Disclosure Guidance and Transparency Rules.